Key Highlights

  • Senti Biosciences (NASDAQ:SNTI) reported a third-quarter net loss of USD 11,586 thousand, down from USD 18,126 thousand, a calculated decline of about 36.1%.
  • Quarterly Research and Development spending fell USD 4.4 million to USD 6.1 million, mainly on USD 3.3 million lower external costs tied to Senti-202.
  • Cash and cash equivalents were USD 5.6 million at September 30, 2026, and management says operations may not continue past the second quarter of 2027.
  • The Merger with an affiliate of Celadon Partners closed October 21, 2026, with stockholders receiving contingent value rights worth up to USD 60.0 million in aggregate payments.

Lower Senti-202 Costs Shrink the Quarterly Loss

Senti Biosciences (NASDAQ:SNTI) is a cell and gene therapy company built around its Regulator Dial technology, with programs in Rett syndrome and armored tumor-infiltrating lymphocytes. Its quarterly report, filed November 16, 2026, shows total operating expenses of USD 12.3 million for the quarter ended September 30, 2026, down from USD 16.9 million. Research and development fell to USD 6.1 million from USD 10.5 million, while general and administrative expense was USD 6.3 million, roughly flat from USD 6.4 million. The company also booked USD 19 thousand of related-party collaboration Revenue from an option extension fee under its BlueRock agreement.

Other items moved in its favor. GeneFab sublease income was USD 992 thousand against a USD 1,567 thousand expense a year earlier, reflecting the Alameda Lease amendment, partly offset by a USD 726 thousand loss on the Fair Value of convertible notes.

Nine-Month Loss Narrows Helped by a USD 6.9 Million Lease Gain

For nine months, net loss was USD 28,557 thousand compared with USD 46,971 thousand. Research and development dropped USD 10.7 million to USD 19.1 million, and general and administrative expense eased USD 1.1 million to USD 19.2 million. A one-time USD 6.9 million gain on lease modification, tied to the March 2026 Alameda lease amendment that halved the leased space to about 46,000 square feet, also reduced operating expenses. Accumulated Deficit reached USD 387.1 million, against USD 358.6 million at the end of 2025.

Financing came from senior secured convertible notes sold to Celadon-linked investors: USD 10.0 million in May, USD 4.0 million in August and USD 2.0 million in September 2026.

Merger Closes, Rett and TIL Programs Remain, and Funding Needs Persist

The merger agreement signed July 14, 2026 closed on October 21, 2026 after stockholder approval. Celadon Partners' affiliate acquired substantially all the existing Business and pipeline held through subsidiaries, and the public company retained the Rett syndrome and TIL programs. No cash was paid to holders at closing; they receive contingent value rights, one per share as of October 30, 2026, with payments of up to USD 60.0 million in aggregate.

Senti sold 7,309,941 shares to a Celadon affiliate for about USD 2.5 million on October 21, and signed a November 9 commitment for up to USD 4.55 million more, subject to conditions including Nasdaq listing. Nasdaq issued a minimum bid price notice on August 27, giving until February 23, 2027 to regain compliance. Shares outstanding were 85,706,263 on October 30, 2026.

Where Things Stand

The quarter captured a company in transition. Senti Biosciences (NASDAQ:SNTI) spent less on research and cut its loss to USD 11.6 million, but cash of USD 5.6 million was not enough to remove Going Concern doubt, and the business that remains is a narrower Rett syndrome and TIL platform. Watch for drawdowns under the new USD 4.55 million Equity commitment, progress on Nasdaq bid price and equity compliance, and any CVR milestone payments that would flow to holders.